New 2023 Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party Group Acute Leukemia Working Party (ALWP) 1st listed author Jesús Duque-Afonso Journal Bone Marrow Transplant.
2023 Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Rémy Duléry Journal Bone Marrow Transplant.
2023 Thiotepa-based regimens are a valid alternative to total body irradiation-based reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Giorgia Battipaglia Journal Transplant Cell Ther.
2023 Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study Group Acute Leukemia Working Party (ALWP) 1st listed author Frédéric Baron Journal Br J Haematol.
2023 Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Francesco Saraceni Journal Hemasphere.
2023 Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) Global Committee 1st listed author Jia Chen Journal Bone Marrow Transplant.
2023 The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2023 Improved post-transplant outcomes in recent years for AML patients with FLT3-ITD and wild-type NPM1: a report from the EBMT acute leukemia working party Group Acute Leukemia Working Party (ALWP) 1st listed author Ali Bazarbachi Journal Clin Cancer Res.
2023 Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Jaime Sanz Journal Bone Marrow Transplant.
2023 Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal J Hematol Oncol.
2023 Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2023 Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Br J Haematol.